USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: MEDROS, INC.
Address: 4041 Forest Park Avenue
Center for Emerging Technologies
St. Louis, MO 63108 2809
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $840,156.00 6
STTR Phase I $164,300.00 1

Award List:

High Throughput Drug Screening in Drosophila for Novel Cancer Therapeutics

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Eduardo J. Martinez
Award Amount: $132,178.00
Abstract:
DESCRIPTION (provided by applicant): Cancer is a growing problem in this country and in the world. It is the second leading cause of death in this country, accounting for nearly one in four deaths. In addition to the human costs, the National Institutes of Health estimate that cancer is estimated… More

High Throughput Drug Screening in Drosophila for Novel Diabetes Therapeutics

Award Year / Program / Phase: 2007 / STTR / Phase I
Agency: HHS
Research Institution: WASHINGTON UNIVERSITY
Principal Investigator: Eduardo J. Martinez
Award Amount: $164,300.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Diabetes mellitus and related metabolic syndrome represent perhaps the fastest growing major disease market in the developing world. Diabetes has recently been described as a global pandemic that affects nearly 200 mi llion people worldwide and costs this… More

Assessing Concentration Levels of Pharmacological Agents in Drosophila

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator: Eduardo J. Martinez
Award Amount: $137,071.00
Abstract:
DESCRIPTION (provided by applicant): The pharmaceutical industry is under mounting pressure to reinvent itself due to high failure rates in the clinic and exorbitant research costs. Larger research and development budgets have not yielded the promised incr ease in medicines entering the marketplace.… More

High Throughput Lethality Screen in Drosophila Against Tumor Metastasis

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator: Eduardo J. Martinez
Award Amount: $132,480.00
Abstract:
DESCRIPTION (provided by applicant): Cancer continues to be a growing health issue. Overall five-year survival rates have changed only marginally over the past three decades and success rates in putting cancer drugs through the clinic have not improved. Th ese facts highlight an unmet need not only… More

Using Drosophila to Screen p38 Inhibitors Targeted to the Liver as Novel Diabetes

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Eduardo J. Martinez
Award Amount: $136,313.00
Abstract:
DESCRIPTION (provided by applicant): Diabetes has reached epidemic proportions in the United States resulting in expenditures of over 90B per year. The enormity of the potential market inspired many pharmaceutical companies to enter the field but success has proven difficult. The reason for this… More

Establishing Drosophila Tools for Pathway Mapping and Target Identification

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Elena M. Gracheva
Award Amount: $150,000.00
Abstract:
DESCRIPTION (provided by applicant): The pharmaceutical industry is under growing scrutiny due to the high failure rate in the clinic and the exorbitant cost of research resulting in expensive medications and growing healthcare expenditures. Increased rese arch and development budgets have had… More

Tunable Insulin Resistance in a Drosophila Model of Diabetes

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Elena M. Gracheva
Award Amount: $152,114.00
Abstract:
DESCRIPTION (provided by applicant): Diabetes has reached epidemic proportions in the United States resulting in expenditures of over 90B per year. The enormity of the potential market inspired many pharmaceutical companies to enter the field but success has proven difficult. The reason for this… More